Updated: December 11, 2025 – Data and news through the latest available trading session. This article is for informational purposes only and is not investment advice.
Key Takeaways
- Share price & performance: Philip Morris International Inc. (NYSE: PM) currently trades around the $150–$152 range, roughly 20% below its 52‑week high of $186.69 reached in mid‑June 2025, after a late‑November and early‑December pullback. [1]
- Guidance reaffirmed: Management reaffirmed 2025 EPS guidance at the Morgan Stanley Global Consumer & Retail Conference on December 2, projecting reported EPS of $7.39–$7.49 and adjusted EPS of $7.46–$7.56, implying low‑ to mid‑teens growth vs. 2024. [2]
- Smoke‑free momentum: Smoke‑free products like IQOS and ZYN now generate about 41% of PMI’s revenue and over 42% of gross profit, with more than 41 million adult users in ~97 markets globally. [3]
- New regulatory catalyst: On November 21, 2025, the U.S. FDA set a January 22, 2026 advisory panel to review an application to market ZYN nicotine pouches as a lower‑risk product—a key potential catalyst for PMI’s U.S. business. [4]
- Analyst view: Wall Street’s consensus rating on PM is “Overweight/Moderate Buy” with an average price target around $184–$189, implying mid‑20% upside from current levels. [5]
- Dividend profile: PMI pays an annual dividend of about $5.88 per share (quarterly $1.47), for a yield near 3.8%–3.9%, and has raised its dividend every year since 2008. [6]
Below is a detailed look at what has happened with Philip Morris International stock since November 21, 2025, and what current news, forecasts and analyses are saying about its outlook.
1. Philip Morris International Stock Today
As of the latest trading data on December 11, 2025, PM shares are trading in the low‑$150s, with intraday data around $150–$152 per share. [7]
Key snapshot:
- Current zone: ~$150–$152
- 52‑week range: roughly $116.12 – $186.69 [8]
- 30‑day range: about $146 – $158, reflecting the late‑November bounce and early‑December selloff. [9]
- 12‑month performance: PM is still up high‑teens percentage over the past year (around 17–18%), outpacing the S&P 500 on several measures, according to independent analyses. [10]
In other words, PMI has given back part of its 2025 rally but remains well above its early‑year levels, sitting in the middle of its 52‑week band.
2. Price Action and News Since November 21, 2025
2.1 Late‑November volatility
Starting from November 21, 2025, PM’s trading has been choppy:
- November 21: Stock closed around $155–$156 with modest losses, on volume just under 7 million shares. [11]
- November 24: Shares fell 2.69% to $151.06, notably underperforming both the S&P 500 and Dow as well as key tobacco peers, on heavy volume (≈12.8 million shares). [12]
- November 25 & 28: PM quickly rebounded, with a +4.2% jump on Nov. 25 and additional gains by Nov. 28, closing above $157 at one point. [13]
Through this period, several factors were in play:
- Profit‑taking after a strong year‑to‑date rally. [14]
- Ongoing debates about valuation after multiple guidance upgrades. [15]
- Growing attention to regulatory and ESG risks in the tobacco and nicotine sector.
2.2 ZYN’s FDA panel: a new U.S. catalyst (Nov. 21, 2025)
On November 21, 2025, the FDA announced that its Tobacco Products Scientific Advisory Committee (TPSAC) will meet on January 22, 2026 to evaluate Swedish Match USA’s application to market ZYN nicotine pouches (a PMI brand) as a modified‑risk product. [16]
The panel will assess:
- Whether scientific evidence supports lower health risk vs cigarettes
- Whether adult consumers understand the proposed claims
- The overall public‑health impact of allowing reduced‑risk marketing
ZYN already saw high‑30s percentage growth in Q3 2025, and PMI has highlighted it as one of its most profitable categories. [17]
Why it matters for the stock:
A positive outcome could strengthen PMI’s U.S. smoke‑free franchise and support the company’s long‑term earnings and valuation narrative. A negative or delayed decision would reinforce regulatory risk.
2.3 Guidance reaffirmed at Morgan Stanley conference (Dec. 2, 2025)
On December 2, 2025, CEO Jacek Olczak presented at the Morgan Stanley Global Consumer & Retail Conference, where PMI reaffirmed its 2025 full‑year outlook originally updated with the Q3 results. [18]
Key points from the forecast:
- Reported diluted EPS:$7.39–$7.49
- Total “adjustments” for one‑offs: about $0.07 per share
- Adjusted diluted EPS:$7.46–$7.56, vs $6.57 in 2024
- Growth:13.5–15.1% on an adjusted basis (12–13.5% excluding currency tailwinds). [19]
This marked at least the third guidance increase in 2025, underscoring management’s confidence in the smoke‑free pivot and resilience in combustible cash flows. [20]
MarketBeat and other outlets subsequently highlighted that PMI’s updated guidance is broadly in line with, or slightly above, consensus analyst estimates. [21]
2.4 Ferrari + ZYN branding: marketing and ESG optics (Dec. 3, 2025)
On December 3, 2025, Philip Morris announced an expanded partnership with Scuderia Ferrari HP, including prominent ZYN branding on Ferrari’s Formula 1 cars at selected races starting with the Abu Dhabi Grand Prix 2025. [22]
Ferrari separately confirmed a renewed multi‑year partnership making PMI a “Premium Partner” of Scuderia Ferrari HP and a Series Partner of the Ferrari Challenge Trofeo Pirelli from January 1, 2026. [23]
For investors, this has two angles:
- Brand power: It keeps PMI and ZYN highly visible on a premium global sports platform with an overwhelmingly adult audience. [24]
- ESG controversy: Tobacco‑sector marketing in sports remains contentious and may attract criticism from health advocates and some ESG‑focused investors.
2.5 Early‑December pullback and institutional flows
Despite reaffirmed guidance and marketing catalysts, PM has slid from the mid‑$150s toward the high‑$140s/low‑$150s in early December, underperforming some peers. MarketWatch flagged a 2.06% drop on December 4 to about $148.58, its fourth straight decline, with above‑average volume. [25]
At the same time, institutional trading in PM remains active:
- The Manufacturers Life Insurance Company trimmed its position by 1.1% in Q2 but still holds nearly 2 million PM shares, and MarketBeat notes a “Moderate Buy” consensus rating with a roughly $189 average target. [26]
- Another MarketBeat filing highlights Sei Investments Co. increasing its PM stake, while CIBC Asset Management and others have modestly reduced holdings—suggesting mixed but engaged institutional sentiment. [27]
- A recent Yahoo Finance piece emphasized that institutions control roughly 82% of PMI’s float, meaning major fund flows can materially influence the share price. [28]
3. Fundamentals: Q3 2025 Results and the Smoke‑Free Pivot
3.1 Q3 2025: Beat‑and‑raise quarter
On October 21, 2025, PMI reported a strong Q3 2025, which still underpins the narrative investors are trading on today: [29]
- Net revenues: about $10.8 billion, up 9.4% year‑over‑year (5.9% organically)
- Smoke‑free business:
- 41% of total net revenues
- Net revenues up 17.7% reported (13.9% organically)
- Gross profit up 19.5% (14.8% organically)
- Combustibles: modest growth, with 4.3% revenue growth and continued gross‑profit expansion despite volume declines
- Adjusted diluted EPS:$2.24, up 17.3% year‑over‑year; $2.16 excluding currency, up 13.1%.
PMI also highlighted strong metrics for key brands:
- IQOS:
- Roughly 76% volume share in the global heat‑not‑burn category
- Solid share gains in Japan, Europe and multiple emerging markets. [30]
- VEEV e‑vapor: shipment volume up about 91%, with top‑three share in many markets. [31]
- ZYN oral nicotine pouches: U.S. volume estimated up around 39% in Q3 with strong profitability. [32]
This performance underpins management’s confidence in the mid‑teens EPS growth trajectory for 2025 and is central to bullish analyst arguments.
3.2 Long‑term transformation: from combustibles to smoke‑free
Several recent analyses (and PMI’s own transformation reporting) stress how far the company has gone in its smoke‑free pivot: [33]
- Smoke‑free products now:
- 41% of total revenue
- Over 42% of total gross profit
- Available in ~97 markets with over 41 million adult users
- PMI targets over two‑thirds of revenue from smoke‑free products by 2030, supported by more than $14 billion invested in R&D and commercialization since 2008. [34]
To reflect this shift, PMI has announced that in 2026 it will reorganize reporting into three segments: International Smoke‑Free, International Combustibles, and U.S., replacing the current four regional segments. [35]
This structural change is meant to give investors clearer visibility into:
- The growth and profitability of the smoke‑free portfolio
- The cash‑generating but declining combustible business
- The increasingly important U.S. market, including ZYN and future IQOS initiatives
4. Analyst Forecasts and Valuation
4.1 Consensus forecasts
Across major data providers, analyst expectations for PMI over the next few years are relatively constructive:
- Adjusted EPS 2025: consensus roughly aligns with PMI’s guidance around $7.46–$7.56. [36]
- Medium‑term growth: Simply Wall St. and similar platforms forecast around 12% annual EPS growth and ~7% revenue growth per year over the next few years. [37]
On the rating side:
- MarketWatch shows an average analyst recommendation of “Overweight”, with an average target price around $184.36 based on 19 ratings. [38]
- Yahoo Finance reports a one‑year target estimate of $182.94. [39]
- MarketBeat’s compilation of recent research puts the consensus target closer to $189, with 12 Buy ratings and only one Hold, for a “Moderate Buy” label. [40]
Taken together, these imply mid‑20s percentage upside versus current prices if the forecasts materialize.
4.2 Valuation metrics and debate
On standard valuation metrics:
- Recent reports cite a P/E ratio in the mid‑20s (around 27x trailing earnings), a PEG ratio below 2, and profit margins above 20%. [41]
- Over the past 10 years, PM has delivered roughly 70% total return, not counting dividends, according to long‑term price series. [42]
Analyst and blogger commentary since November 21 has split into a few camps:
- Bullish cases
- Seeking Alpha authors describe PM as a “tobacco powerhouse” that remains “reasonably priced” given its smoke‑free growth and robust cash flows, even after the 2025 rally. [43]
- A Simply Wall St. article and related coverage argue that after reaffirming guidance, the stock may be “mispriced” relative to its cash‑generation potential and high‑quality growth, suggesting fair value in the $180+ range. [44]
- More cautious views
- AInvest and similar platforms highlight that while PM’s dividend yield is attractive, the payout ratio above 100% of earnings raises sustainability questions if earnings growth were to slow. [45]
- Another AInvest note frames PM as a “risk defense” value idea, but warns that the P/E is now above sector averages, with regulatory uncertainty potentially capping near‑term upside despite DCF fair value models above $200. [46]
The result is a healthy debate: many professionals view the current pullback as an opportunity, while others see the stock as solid but not obviously cheap given its regulatory and ESG headwinds.
5. Dividend Outlook: A Key Part of the PM Story
5.1 Current dividend and recent increase
Dividend‑oriented investors continue to focus heavily on PM’s payout:
- Quarterly dividend:$1.47 per share, up from $1.35, representing an 8.9% increase announced in September 2025. [47]
- Annualized dividend: about $5.88 per share, implying a yield around 3.8–3.9% at current prices. [48]
- Track record: PMI has raised its dividend every year since its 2008 spin‑off, a 17‑year streak as of 2025. [49]
PMI’s own disclosures show a Q4 2025 dividend calendar with: [50]
- Declaration date: December 12, 2025
- Ex‑dividend date & record date: December 26, 2025
- Payment date: January 14, 2026
(Investors should confirm final details on PMI’s investor relations site or with their broker, as dates and amounts can be updated.)
5.2 Payout ratio and sustainability debate
The flip side of PMI’s generous dividend is its high payout ratio:
- Some data providers estimate the payout ratio at roughly 100–117% of trailing earnings, depending on the earnings definition used. [51]
Supporters argue that:
- PMI’s business throws off stable, resilient cash flows, and
- Smoke‑free growth plus limited capex needs justify a high payout.
Skeptics counter that:
- A payout near or above 100% leaves little margin of safety if regulation, litigation, or macro shocks hit earnings, potentially forcing slower dividend growth over time. [52]
So far, management has consistently prioritized dividend stability and gradual growth, but the sustainability of high single‑digit raises will likely depend on delivering the promised double‑digit EPS growth.
6. Key Risks and Regulatory Backdrop
Even bullish analyses emphasize that PMI faces non‑trivial risk factors, many of which have been highlighted in recent news since November 21:
6.1 FDA and modified‑risk decisions
Beyond the upcoming ZYN MRTP hearing in January 2026, PMI also remains engaged with the FDA over IQOS’s modified‑risk marketing status. The company has previously urged an FDA advisory committee to continue allowing IQOS to be sold as a modified‑risk tobacco product, emphasizing its scientific evidence and usage patterns among adult smokers. [53]
Decisions around:
- ZYN’s risk claims, and
- The regulatory treatment of heated tobacco and nicotine pouches
will directly influence PMI’s growth, pricing power and marketing freedoms in its most profitable market.
6.2 EU transparency and lobbying concerns
On December 10, 2025, a report by anti‑tobacco groups accused EU institutions of underreporting meetings with tobacco companies, including PMI, and criticized perceived non‑compliance with WHO’s Framework Convention on Tobacco Control transparency rules. [54]
The report does not claim PMI broke laws, but it:
- Highlights ongoing scrutiny of tobacco lobbying
- May embolden regulators to pursue stricter engagement rules and regulations in key markets
This adds to the broader ESG headwinds that some investors factor into their valuation discount for PM and other tobacco names.
6.3 Litigation, taxation and ESG
PMI itself warns in its forward‑looking statements of risks from: [55]
- Excise tax increases and discriminatory tax structures
- Litigation related to tobacco and nicotine products
- Currency volatility, particularly in emerging markets
- Illicit trade and counterfeit products
- Political and macroeconomic instability in certain geographies
With smoke‑free products now a large part of the business, PMI must also navigate evolving regulations for new nicotine formats (pouches, e‑vapor, heated tobacco), often under intense public‑health scrutiny.
7. Debt Management and Balance Sheet Moves
A notable financial move in the period around November 21:
- PMI announced it would redeem all outstanding 4.875% notes due February 13, 2026 (about $1.7 billion), with redemption scheduled for December 4, 2025. [56]
Analysts interpret this as:
- A sign of active capital‑structure management, taking advantage of PMI’s strong cash generation
- Potentially reducing interest expense over time, though the effect on EPS is modest
Combined with its dividend and share‑based compensation, PMI’s capital allocation remains shareholder‑friendly but leverage‑sensitive—another factor in how rating agencies and investors view risk.
8. What Could Move PM Stock Next?
Looking ahead from December 11, 2025, several events and themes are likely to shape PM’s share price:
- FDA’s ZYN MRTP decision (post‑Jan 22, 2026)
- A positive vote from TPSAC and later authorization could validate PMI’s harm‑reduction thesis and unlock more differentiated marketing in the U.S. [57]
- Q4 2025 results and 2026 guidance
- Investors will watch whether PMI can sustain double‑digit EPS growth and expand smoke‑free margins, while managing promotional spending on ZYN and IQOS. [58]
- Implementation of new reporting segments in 2026
- The International Smoke‑Free / International Combustibles / U.S. structure should give markets clearer line‑of‑sight into the profitability and growth of each pillar. [59]
- Dividend actions
- With a new dividend declaration expected December 12, 2025, investors will monitor whether PM maintains its current payout pace and how the forward yield compares to bond yields after recent rate cuts. [60]
- ESG & regulatory headlines
- Reports like the recent EU transparency study and ongoing debates about nicotine pouches and heated tobacco may influence valuation multiples, even if near‑term earnings remain strong. [61]
9. Is Philip Morris International Stock Attractive After the Recent Pullback?
From November 21, 2025 to today, PM has moved through a mini‑cycle:
- Fundamentals: Q3 results and reiterated guidance confirm mid‑teens EPS growth powered by smoke‑free products. [62]
- Valuation: The stock has corrected from its summer highs but still trades at a premium P/E to the broader staples sector, with DCF‑style models often implying fair value in the $180–$200 range. [63]
- Income appeal: A near‑4% yield and long dividend track record remain key attractions, albeit with a high payout ratio that requires continued earnings execution. [64]
Whether PM fits your portfolio depends on your priorities:
- Investors who prioritize income and defensive cash flows, and who are comfortable with tobacco‑sector ESG and regulation, may view PM as a high‑quality, reasonably‑valued dividend compounder with potential upside if smoke‑free growth remains strong.
- Investors who avoid “sin stocks”, or who are very sensitive to regulatory and headline risk, may prefer to watch from the sidelines or demand a larger valuation discount before getting involved.
As always, anyone considering PM—or any stock—should:
- Assess their risk tolerance, time horizon and income needs
- Diversify rather than relying heavily on any single company or sector
- Consider speaking with a qualified financial adviser before making investment decisions
References
1. www.tradingview.com, 2. www.pmi.com, 3. www.pmi.com, 4. www.reuters.com, 5. www.marketwatch.com, 6. www.pmi.com, 7. www.tradingview.com, 8. stockinvest.us, 9. stockinvest.us, 10. www.financecharts.com, 11. www.investing.com, 12. www.marketwatch.com, 13. www.investing.com, 14. www.indexbox.io, 15. www.reuters.com, 16. www.reuters.com, 17. www.pmi.com, 18. www.pmi.com, 19. www.pmi.com, 20. finviz.com, 21. www.marketbeat.com, 22. www.businesswire.com, 23. www.ferrari.com, 24. www.businesswire.com, 25. www.marketwatch.com, 26. www.marketbeat.com, 27. www.marketbeat.com, 28. finance.yahoo.com, 29. www.pmi.com, 30. www.pmi.com, 31. www.pmi.com, 32. www.pmi.com, 33. www.businessinsider.com, 34. www.businessinsider.com, 35. www.pmi.com, 36. www.pmi.com, 37. simplywall.st, 38. www.marketwatch.com, 39. finance.yahoo.com, 40. www.marketbeat.com, 41. www.marketbeat.com, 42. finviz.com, 43. seekingalpha.com, 44. finance.yahoo.com, 45. www.ainvest.com, 46. www.ainvest.com, 47. www.pmi.com, 48. stockanalysis.com, 49. www.pmi.com, 50. www.pmi.com, 51. stockanalysis.com, 52. www.ainvest.com, 53. www.pmi.com, 54. www.reuters.com, 55. www.pmi.com, 56. simplywall.st, 57. www.reuters.com, 58. www.pmi.com, 59. www.pmi.com, 60. www.pmi.com, 61. www.reuters.com, 62. www.pmi.com, 63. www.indexbox.io, 64. stockanalysis.com
